2 August 2012 - MAP Pharmaceuticals Inc (Nasdaq: MAPP), a biopharmaceutical company focused on developing and commercialising new therapies to address patient needs in neurology, has announced today that it has issued an underwritten public offering of 3,880,598 shares of its common stock at a price of USD13.40 per share to the public.

The company aims to raise around USD52m from the offering.